A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
暂无分享,去创建一个
Kristy M Ainslie | Ning Cheng | Leaf Huang | David B. Darr | J. Ting | K. Ainslie | Leaf Huang | Lei Miao | S. Montgomery | K. McKinnon | Hong Yuan | Hong Yuan | Jenny P-Y Ting | Qi Liu | Rebekah Watkins-Schulz | Robert D Junkins | Clément N David | Brandon M Johnson | Stephanie A Montgomery | Kevin J Peine | David B Darr | Karen P McKinnon | Qi Liu | Lei Miao | Eric M Bachelder | E. Bachelder | R. Junkins | K. Peine | Rebekah Watkins-Schulz | Brandon M. Johnson | Clément N. David | Ning Cheng | Clement N David
[1] Will Liao,et al. The cellular and molecular origin of tumor-associated macrophages , 2014, Science.
[2] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[3] S. Coffelt,et al. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. , 2015, Trends in immunology.
[4] M. David,et al. Immunomodulatory functions of type I interferons , 2012, Nature Reviews Immunology.
[5] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[6] G. Barber,et al. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling , 2008, Nature.
[7] Laura A. Sullivan,et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts , 2009, Molecular Cancer Therapeutics.
[8] P. Zhu,et al. Sox2 functions as a sequence-specific DNA sensor in neutrophils to initiate innate immunity against microbial infection , 2015, Nature Immunology.
[9] Xuetao Cao,et al. The origin and function of tumor-associated macrophages , 2014, Cellular and Molecular Immunology.
[10] P. Hwu,et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.
[11] G. Freeman,et al. PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.
[12] I. Mellman,et al. Elements of cancer immunity and the cancer–immune set point , 2017, Nature.
[13] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[14] John Condeelis,et al. Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.
[15] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[16] K. Flaherty,et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.
[17] J. Taylor‐Papadimitriou,et al. Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast , 1978, International journal of cancer.
[18] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[19] R. Schreiber,et al. The three Es of cancer immunoediting. , 2004, Annual review of immunology.
[20] Xue Han,et al. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.
[21] V. Cryns,et al. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. , 2011, Molecular endocrinology.
[22] T. Gajewski,et al. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer , 2015, Clinical Cancer Research.
[23] Lajos Pusztai,et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Joel C Sunshine,et al. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. , 2018, Nanomedicine : nanotechnology, biology, and medicine.
[25] C. Lewis,et al. Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.
[26] L. Molinero,et al. Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) , 2015 .
[27] Jedd D. Wolchok,et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy , 2016, Nature Reviews Clinical Oncology.
[28] V. Torchilin,et al. ATP-loaded liposomes for targeted treatment in models of myocardial ischemia. , 2010, Methods in molecular biology.
[29] J. Green,et al. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[30] G. Cheng,et al. Positive Feedback Regulation of Type I IFN Production by the IFN-Inducible DNA Sensor cGAS , 2015, The Journal of Immunology.
[31] Charles M Perou,et al. Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models , 2014, Clinical Cancer Research.
[32] D. Scherman,et al. Formulation and evaluation of ATP-containing liposomes including lactosylated ASGPr ligand , 2009, Journal of liposome research.
[33] S. Lucas,et al. Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies , 2017, Front. Immunol..
[34] G. Natoli,et al. Macrophages and cancer: from mechanisms to therapeutic implications. , 2015, Trends in immunology.
[35] P. Allavena,et al. Immunology in the clinic review series; focus on cancer: tumour‐associated macrophages: undisputed stars of the inflammatory tumour microenvironment , 2012, Clinical and experimental immunology.
[36] J. Pollard. Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.
[37] Zhijian J. Chen,et al. cGAS is essential for the antitumor effect of immune checkpoint blockade , 2017, Proceedings of the National Academy of Sciences.
[38] Cheryl Jorcyk,et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma , 2000, Oncogene.
[39] A. Mantovani,et al. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.
[40] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[41] Zhijian J. Chen,et al. A STING-Activating Nanovaccine for Cancer Immunotherapy , 2017, Nature nanotechnology.
[42] R. Salgia,et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations , 2018, Journal of Immunotherapy for Cancer.
[43] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[44] H. Fiegl,et al. In situ proliferation contributes to accumulation of tumor‐associated macrophages in spontaneous mammary tumors , 2014, European journal of immunology.
[45] Jeffrey S. Damrauer,et al. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. , 2014, The Journal of clinical investigation.
[46] Matheus C. Bürger,et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy , 2016, Nature.
[47] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[48] Ying Wang,et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.
[49] D. Fraker,et al. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. , 2003, Cancer research.
[50] Ronald A. DePinho,et al. Model organisms: The mighty mouse: genetically engineered mouse models in cancer drug development , 2006, Nature Reviews Drug Discovery.
[51] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[52] L. Coussens,et al. Differential macrophage programming in the tumor microenvironment. , 2012, Trends in immunology.
[53] George E. Katibah,et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.
[54] Xiangshi Tan,et al. Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response , 2016, Scientific Reports.
[55] P. Kantoff,et al. Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.
[56] Zhijian J. Chen,et al. Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.
[57] Y. Li,et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. , 2008, Immunity.
[58] R. Sullivan,et al. Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies , 2016, Cancer.
[59] P. Chanson,et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[60] N. Van Rooijen,et al. Liposomes for specific depletion of macrophages from organs and tissues. , 2010, Methods in molecular biology.
[61] Chi-Ping Day,et al. Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges , 2015, Cell.
[62] G. Zhu,et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.
[63] M. Rantalainen,et al. Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. , 2016, Cell reports.